Director/PDMR Share Dealings

October 24, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
it was notified today that Flemming Ornskov, MD, Chief Executive Officer of the
Company, acquired 15,500 ordinary shares of 5 pence each in the Company
("Shares") today at an average price of £40.42 per share. The transaction took
place on the London Stock Exchange.

Following the above transaction, Dr Ornskov holds 37,500 Shares. He also holds
awards of Stock Appreciation Rights, Performance Shares and Deferred Shares
over 187,401 ADSs. One ADS is equal to three Shares.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Jeff Poulton                            jpoulton@shire.com   +1 781 482 0945
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157

Media
Stephanie Fagan                         sfagan@shire.com     +1 781 482 0460
Gwen Fisher                             gfisher@shire.com    +1 484 595 9836

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmology.

www.shire.com


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com